Search

Long-lasting, late-onset, and chronic idiopathic neutropenia project, February 2025 update

A project update from Dr Grigorios Tsaknakis.

Highlights of Past EHA (HOPE) Asia 2021

For the third edition of the Highlights of Past EHA (HOPE) Asia, EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

“Follow your dreams! Go for it!” – Verena Gaidzik, woman in hematology/EHA volunteer

Mar 15 2019

Verena Gaidzik is a physician scientist in the department of Internal Medicine III (Head: Prof. Dr. Hartmut Döhner) at the University Hospital of Ulm. She has board certifications in internal medicine, hematology and oncology as well as palliative medicine.

EHA, in partnership with ISTH, award two fellows to support global educational opportunities

Nov 27 2018

EHA and the International Society on Thrombosis and Hemostasis (ISTH) jointly awarded two joint ISTH-EHA Training Fellowships to Araci Rondon (The Netherlands) and Dianne van der Wal (Australia).

EU funding calls for hematology

Horizon Europe
European partnership for pandemic preparedness (November 26, 2024)
Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) (deadline: November 26, 2024)
MSCA Doctoral Networks 2024 (deadline: November 27, 2024)
MSCA…

Publications

Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Ocul Surf. 2019 Jan 7.

Program

All session times are in Eastern European Time (EET).

Publications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Jun 14 2013

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.